TY - JOUR
T1 - Low Dose Naltrexone in Dermatology
AU - Jaros, Joanna
AU - Lio, Peter
PY - 2019/3/1
Y1 - 2019/3/1
N2 - Low-dose naltrexone (LDN) has been successfully studied as an immunomodulatory and anti-inflammatory therapy in a wide range of conditions including Crohn’s disease, fibromyalgia, major depressive disorder, cancer, chronic regional pain syndrome, Charcot-Marie-Tooth, and multiple sclerosis.1-5 Recently, off label LDN has been shown to improve dermatologic conditions such as systemic sclerosis, Hailey-Hailey Disease, lichen planopilaris, and guttate psoriasis.6-9 In this article, we examine the existing evidence for use of LDN in skin disease and discuss its potential application in the treatment of atopic dermatitis (AD). J Drugs Dermatol. 2019;18(3):235-238.
AB - Low-dose naltrexone (LDN) has been successfully studied as an immunomodulatory and anti-inflammatory therapy in a wide range of conditions including Crohn’s disease, fibromyalgia, major depressive disorder, cancer, chronic regional pain syndrome, Charcot-Marie-Tooth, and multiple sclerosis.1-5 Recently, off label LDN has been shown to improve dermatologic conditions such as systemic sclerosis, Hailey-Hailey Disease, lichen planopilaris, and guttate psoriasis.6-9 In this article, we examine the existing evidence for use of LDN in skin disease and discuss its potential application in the treatment of atopic dermatitis (AD). J Drugs Dermatol. 2019;18(3):235-238.
UR - http://www.scopus.com/inward/record.url?scp=85063798685&partnerID=8YFLogxK
M3 - Article
C2 - 30909326
AN - SCOPUS:85063798685
SN - 1545-9616
VL - 18
SP - 235
EP - 238
JO - Journal of Drugs in Dermatology
JF - Journal of Drugs in Dermatology
IS - 3
ER -